The current "instruments and tools used to assess the value of cancer medicines may be too “blunt” to capture the true potential of future therapies and technologies to treat small patient populations, says a discussion paper released by Rare Cancers Australia.
Latest Video
New Stories
-
Pharmac announces 90-day dispensed quantities of HIV medicines
November 27, 2025 - - Latest News -
Landmark report warns Australia’s hospital pharmacy system is at an 'inflection point'
November 27, 2025 - - Latest News -
Australia releases first national estimate of women living with metastatic breast cancer
November 27, 2025 - - Latest News -
Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours
November 27, 2025 - - Australian Biotech -
Algorae Pharmaceuticals secures new supply of chemotherapy for Australia through Dr Reddy’s partnership
November 27, 2025 - - Latest News -
An interview that reminds us of the missing discussion in Australia
November 27, 2025 - - Latest News -
Neurizon Therapeutics entering 'a promising new horizon” as ALS program advances
November 26, 2025 - - Australian Biotech
